Deutsche Bank Ag\ Innoviva, Inc. Call Options Transaction History

Deutsche Bank Ag\

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$16.33 - $20.04 $408,249 - $501,000	25,000 New	25,000 $482,000
Q1 2024 May 15, 2024	SELL	$14.56 - $16.78 $1.27 Million - $1.47 Million	-87,400 Reduced 77.21%	25,800 $393,000
Q4 2023 Feb 14, 2024	BUY	$12.32 - $16.27 $1.09 Million - $1.44 Million	88,200 Added 352.8%	113,200 $1.82 Million
Q3 2023 Nov 09, 2023	BUY	$12.37 - $13.89 $309,250 - $347,250	25,000 New	25,000 $324,000
Q1 2019 May 15, 2019	BUY	$13.69 - $20.06 $27,380 - $40,120	2,000 New	2,000 $28,000

228

78.7M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.2B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.